Cleveland Clinic Center for Continuing Education:
"Low Vitamin D Ups Mortality Risk in Patients With Diabetes
But risk is independent of urinary micro/macro albumin excretion rate
FRIDAY, Nov. 5 (HealthDay News) -- Low vitamin D levels increase the risk of all-cause mortality in patients with diabetes but do not appear to specifically increase the risk of progression to micro- or macroalbuminuria, according to research published in the October issue of Diabetes Care.
Christel Joergensen, M.D., of the Steno Diabetes Center in Gentofte, Denmark, and colleagues conducted a longitudinal observational follow-up study of 289 patients with type 2 diabetes and normoalbuminuria to assess vitamin D level as a predictor of progression to micro- or macroalbuminuria, all-cause, and cardiovascular mortality.
The researchers found that, in the study group, the mean vitamin D level was 35.7 nmol/L and was not associated with glomerular filtration rate, urinary albumin excretion rate, or A1C level at baseline. Over the study period, those with severe vitamin D deficiency were at higher risk of all-cause mortality and cardiovascular mortality but were not at significantly increased risk of progression to micro- or macroalbuminuria.
'In summary, baseline levels of 25-hydroxyvitamin D3 [25(OH)D3] less than the 10th percentile predict increased risk of all-cause and cardiovascular mortality in type 2 diabetic patients,' the authors write. 'Baseline levels of 25(OH)D3 less than the 10th percentile do not predict progression to micro- or macroalbuminuria.'
Abstract
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment